## **Core Concept**
Beta-2 microglobulin (B2M) is a protein found on the surface of many cells and is a component of the major histocompatibility complex (MHC) class I. It is used as a tumor marker for certain types of cancers, particularly those affecting the immune system.

## **Why the Correct Answer is Right**
Beta-2 microglobulin is specifically used as a tumor marker for **multiple myeloma** and certain types of **lymphomas**. Elevated levels of B2M in the blood can indicate the presence of these malignancies, as well as their progression or response to treatment. The mechanism behind its utility as a tumor marker involves the increased turnover of cells in these cancers, leading to the release of B2M into the bloodstream.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Not specified, but if considering common tumor markers, for example, **CEA (Carcinoembryonic antigen)** for colorectal cancer, B2M is not primarily associated with these types of cancers.
- **Option B:** Similarly, without a specific option provided, if we consider tumor markers like **PSA (Prostate-Specific Antigen)** for prostate cancer, B2M is not a marker for this condition.
- **Option C:** If another specific cancer or marker is considered, B2M's relevance is mainly confined to hematological malignancies like multiple myeloma.

## **Clinical Pearl / High-Yield Fact**
A key clinical point to remember is that **elevated beta-2 microglobulin levels** are not only indicative of multiple myeloma but also **correlate with tumor burden and prognosis**. High levels are associated with a poorer prognosis. This makes B2M an important marker for monitoring disease progression and response to therapy.

## **Correct Answer:** D. Multiple Myeloma.